On Monday, Shares of Century Aluminum Co (NASDAQ:CENX), gained 21.81% to $6.31.
Century Aluminum Company stated a net loss of $33.9 million ($0.39 per common share) for the second quarter of 2015. Results comprise a $30.9 million impairment charge ($0.35 per common share) related to the permanent closure of our Ravenswood smelter and a $25.7 million charge ($0.30 per common share) for lower of cost or market inventory adjustments. Results were also negatively influenced by $11.7 million ($0.13 per common share) in costs related to the labor disruption at our Hawesville smelter. Lastly, results comprise a $10.3 million ($0.12 per common share) unrealized gain on the fair value of contingent consideration related to the acquisition of the remaining 50.3% interest of Mt. Holly. After consideration of these items, the company stated adjusted net income of $24.1 million and adjusted earnings per share of $0.25.
For the second quarter of 2014, Century stated net income of $20.3 million ($0.21 per common share). Results were negatively influenced by a charge of $0.5 million ($0.01 per common share) for the finalization of a legal settlement.
Century Aluminum Company, together with its auxiliaries, produces primary aluminum in the United States and Iceland. It produces standard grade and value-added primary aluminum products; and carbon products, such as anodes and cathodes.
Shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX), declined -0.60% to $4.95, during its last trading session.
Pernix Therapeutics Holdings declared financial results for the second quarter ended June 30, 2015.
Second Quarter Financial Highlights:
- Net revenues on a normalized basis, raised 151% year-over-year, and 29% sequentially as compared to Q1 2015 levels
- Adjusted EBITDA raised to $7.9 million, contrast to a loss of $4.0 million last year
- Priced $130 million of 4.25% Convertible Senior Notes due 2021
- Accomplished exchange offer for $65 million, 8% convertible notes, removing this obligation from Company’s capital structure
- Improved blended cost of capital to about 9%
“Pernix is focused on driving value. During the quarter, we continued to positively direct the trajectory of the Treximet business and we are encouraged by the product’s recent performance as we continue to take aggressive steps to grow this franchise. We have dealt with the issues we faced at the re-launch, counting the lack of samples, and the perception by physicians of limited insurance coverage. While navigating an increasingly challenging managed care environment, we maintained good commercial coverage for over 86% of prescriptions, while stabilizing gross-to-nets. As a result of these efforts, combined with improved promotional efforts by our field force, volumes are increasing, and we are happy by the recent prescription growth, said Doug Drysdale, Chairman and Chief Executive Officer.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product comprise CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product.
Finally, Valley National Bancorp (NYSE:VLY), ended its last trade with 1.10% gain, and closed at $10.07.
Valley National Bancorp, stated net income for the second quarter of 2015 of $32.0 million, or $0.14 per diluted common share as contrast to net income of $30.3 million, or $0.13 per diluted common share, for the first quarter of 2015 and the second quarter of 2014 earnings of $29.5 million, or $0.15 per diluted common share
Valley National Bancorp operates as the holding company for the Valley National Bank that provides commercial, retail, insurance, and wealth administration financial services products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
